TLR9 and Glioma: Friends or Foes?

Toll-like receptor 9 (TLR9) is an intracellular innate immunity receptor that plays a vital role in chronic inflammation and in recognizing pathogenic and self-DNA in immune complexes. This activation of intracellular signaling leads to the transcription of either immune-related or malignancy genes through specific transcription factors. Thus, it has been hypothesized that TLR9 may cause glioma. This article reviews the roles of TLR9 in the pathogenesis of glioma and its related signaling molecules in either defending or promoting glioma. TLR9 mediates the invasion-induced hypoxia of brain cancer cells by the activation of matrix metalloproteinases (2, 9, and 13) in brain tissues. In contrast, the combination of the TLR9 agonist CpG ODN to radiotherapy boosts the role of T cells in antitumor effects. The TLR9 agonist CpG ODN 107 also enhances the radiosensitivity of human glioma U87 cells by blocking tumor angiogenesis. CpG enhances apoptosis in vitro and in vivo. Furthermore, it can enhance the antigen-presenting capacity of microglia, switch immune response toward CD8 T cells, and reduce the number of CD4CD25 Treg cells. CpG ODN shows promise as a potent immunotherapeutic drug against cancer, but specific cautions should be taken when activating TLR9, especially in the case of glioblastoma.

Automated summary

Toll-like receptor 9 (TLR9) is an intracellular innate immunity receptor that plays a crucial role in chronic inflammation and recognizes pathogenic and self-DNA. Activation of TLR9 leads to the transcription of immune-related or malignancy genes through specific transcription factors. This article reviews the roles of TLR9 in glioma pathogenesis and its related signaling molecules in defending or promoting glioma. TLR9 mediates invasion-induced hypoxia in brain cancer cells by activating matrix metalloproteinases. On the other hand, the TLR9 agonist CpG ODN enhances the antitumor effects of T cells when combined with radiotherapy.